

# Myelodysplastic Syndrome - Pipeline Review, H1 2020

<https://marketpublishers.com/r/MF77F037B45EN.html>

Date: June 2020

Pages: 1667

Price: US\$ 2,000.00 (Single User License)

ID: MF77F037B45EN

## Abstracts

Myelodysplastic Syndrome - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2020, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 2, 13, 89, 72, 1, 5, 29 and 3 respectively. Similarly, the

Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 9, 5 and 3 molecules, respectively.

Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).

The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Myelodysplastic Syndrome - Overview

Myelodysplastic Syndrome - Therapeutics Development

Myelodysplastic Syndrome - Therapeutics Assessment

Myelodysplastic Syndrome - Companies Involved in Therapeutics Development

Myelodysplastic Syndrome - Drug Profiles

Myelodysplastic Syndrome - Dormant Projects

Myelodysplastic Syndrome - Discontinued Products

Myelodysplastic Syndrome - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Myelodysplastic Syndrome, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Myelodysplastic Syndrome - Pipeline by 4SC AG, H1 2020

Myelodysplastic Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020

Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Acrotech Biopharma LLC, H1 2020

Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H1 2020

Myelodysplastic Syndrome - Pipeline by ALX Oncology Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Amphivena Therapeutics Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Angiocrine Bioscience Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020

Myelodysplastic Syndrome - Pipeline by Apogenix AG, H1 2020

Myelodysplastic Syndrome - Pipeline by Aprea Therapeutics AB, H1 2020

Myelodysplastic Syndrome - Pipeline by Aptabio Therapeutics Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Aptevo Therapeutics Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Aptose Biosciences Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by Y-Biologics Inc, H1 2020

Myelodysplastic Syndrome - Pipeline by ZIOPHARM Oncology Inc, H1 2020

Myelodysplastic Syndrome - Dormant Projects, H1 2020

## Myelodysplastic Syndrome - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Myelodysplastic Syndrome, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

4SC AG  
A. Menarini Industrie Farmaceutiche Riunite Srl  
AbbVie Inc  
Accelaron Pharma Inc  
Acrotech Biopharma LLC  
Actinium Pharmaceuticals Inc  
Aeglea BioTherapeutics Inc  
Agiros Pharmaceuticals Inc  
AIMM Therapeutics BV  
ALX Oncology Inc  
Amphivena Therapeutics Inc  
Angiocrine Bioscience Inc  
Anhui Anke Biotechnology (Group) Co Ltd  
Apogenix AG  
Aprea Therapeutics AB  
AptaBio Therapeutics Inc  
Aptevo Therapeutics Inc  
Aptose Biosciences Inc  
Argenx SE  
Ascentage Pharma Group International  
Astellas Pharma Inc

Astex Pharmaceuticals Inc  
AstraZeneca Plc  
Atara Biotherapeutics Inc  
Aurigene Discovery Technologies Ltd  
Bayer AG  
Bellicum Pharmaceuticals Inc  
BerGenBio ASA  
Bio-Path Holdings Inc  
BioLineRx Ltd  
BioMed Valley Discoveries Inc  
BioTheryX Inc  
Boehringer Ingelheim International GmbH  
Boston Biomedical Inc  
Bristol-Myers Squibb Co  
Calithera Biosciences Inc  
CellCentric Ltd  
Cellenkos Inc  
Cellerant Therapeutics Inc  
Celularity Inc  
Celyad Oncology  
CheckPoint Immunology Inc  
Chimerix Inc  
China NT Pharma Group Co Ltd  
Chordia Therapeutics Inc  
Cleave Therapeutics Inc  
Constellation Pharmaceuticals Inc  
CrystalGenomics Inc  
Cyclacel Pharmaceuticals Inc  
Daiichi Sankyo Co Ltd  
DC Prime BV  
Deciphera Pharmaceuticals Inc  
Denovo Biopharma LLC  
DiNonA Inc  
Elixirgen Therapeutics LLC  
ExCellThera Inc  
Fate Therapeutics Inc  
Forma Therapeutics Inc  
Fujifilm Holdings Corp  
Gadeta BV



Gamida Cell Ltd  
Geron Corp  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
GlycoMimetics Inc  
GT Biopharma Inc  
H3 Biomedicine Inc  
Harrow Health Inc  
Helocyte Biosciences Inc  
HemoGenyx LLC  
Hutchison MediPharma Ltd  
I-Mab Biopharma Co Ltd  
iCell Gene Therapeutics LLC  
IGF Oncology LLC  
Imago BioSciences Inc  
Immune System Key Ltd  
ImmunityBio Inc  
ImmunoGen Inc  
Incysus Therapeutics Inc  
Incyte Corp  
Inmune Bio Inc  
Io Therapeutics Inc  
Jasper Therapeutics Inc  
Jazz Pharmaceuticals Plc  
Johnson & Johnson  
Juno Therapeutics Inc  
Karyopharm Therapeutics Inc  
Keros Therapeutics Inc  
Kiadis Pharma NV  
Les Laboratoires Servier SAS  
Lixte Biotechnology Holdings Inc  
MacroGenics Inc  
Magenta Therapeutics Inc  
Mana Therapeutics Inc  
Marker Therapeutics Inc  
Mateon Therapeutics Inc  
MediGene AG  
Medivir AB  
MedPacto Inc

MEI Pharma Inc  
Merck & Co Inc  
Merus NV  
Millennium Pharmaceuticals Inc  
Molecular Templates Inc  
Mustang Bio Inc  
Nanjing Legend Biotech Co Ltd  
NantKwest Inc  
Nemucore Medical Innovations Inc  
Newave Pharmaceutical Inc  
NexImmune Inc  
Nkarta Inc  
Nohla Therapeutics Inc  
Novartis AG  
Oncoceutics Inc  
Oncoheroes Biosciences Inc  
Onconova Therapeutics Inc  
Oncotelic Inc  
OncoTherapy Science Inc  
Ono Pharmaceutical Co Ltd  
Opsona Therapeutics Ltd  
Orca Biosystems Inc  
Orsenix Holdings BV  
Oxstem Ltd  
PersImmune Inc  
Pfizer Inc  
Pharma Mar SA  
Pinotbio Inc  
Plexxikon Inc  
Prelude Therapeutics Inc  
PRISM Pharma Co Ltd  
Rafael Pharmaceuticals Inc  
Ryvu Therapeutics SA  
Sanofi  
Seattle Genetics Inc  
Sensei Biotherapeutics Inc  
Shanghai Yingli Pharmaceutical Co Ltd  
Silence Therapeutics Plc  
Sino Biopharmaceutical Ltd

SiNOPSEE Therapeutics Pte Ltd  
SpecificiT Pharma Inc  
Stelexis Therapeutics LLC  
Sumitomo Dainippon Pharma Co Ltd  
Surface Oncology Inc  
Syntrix Biosystems Inc  
Tacitus Therapeutics Inc  
Takara Bio Inc  
Teva Pharmaceutical Industries Ltd  
TheraPharm Deutschland GmbH  
Toko Pharmaceutical Industries Co Ltd  
Tolero Pharmaceuticals Inc  
TOT Biopharm Co Ltd  
Treadwell Therapeutics Inc  
Trethera Corp  
Trillium Therapeutics Inc  
Vyriad Inc  
Y-Biologics Inc  
ZIOPHARM Oncology Inc

## I would like to order

Product name: Myelodysplastic Syndrome - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/MF77F037B45EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MF77F037B45EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970